Several other equities analysts also recently issued reports on IRWD. ValuEngine raised shares of Ironwood Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, January 7th. Cowen set a $12.00 price target on shares of Ironwood Pharmaceuticals and gave the company a hold rating in a research note on Friday, September 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $14.50.
Shares of Ironwood Pharmaceuticals stock opened at $12.95 on Friday. Ironwood Pharmaceuticals has a fifty-two week low of $7.91 and a fifty-two week high of $15.21. The firm has a market capitalization of $1.96 billion, a P/E ratio of -13.63 and a beta of 1.91. The company’s 50 day moving average price is $12.92 and its two-hundred day moving average price is $10.60.
Several hedge funds have recently added to or reduced their stakes in IRWD. Amundi Pioneer Asset Management Inc. bought a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at $63,000. Prudential Financial Inc. raised its stake in shares of Ironwood Pharmaceuticals by 9.6% during the second quarter. Prudential Financial Inc. now owns 14,124 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 1,240 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at $135,000. Bank of Montreal Can raised its stake in Ironwood Pharmaceuticals by 583.9% during the second quarter. Bank of Montreal Can now owns 15,373 shares of the biotechnology company’s stock worth $168,000 after buying an additional 13,125 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Ironwood Pharmaceuticals by 6.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 906,657 shares of the biotechnology company’s stock worth $9,919,000 after buying an additional 56,283 shares during the last quarter.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Recommended Story: What Are Cryptocurrencies?
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.